 Home > Active Ingredient News > Drugs Articles > Sinopharm officially announced phase 3 clinical data of two new crown inactivated vaccines

Sinopharm officially announced phase 3 clinical data of two new crown inactivated vaccines

 Last Update: 2021-06-01
 Source: Internet
 Author: User

Tags

journal journal

caribbean journal

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On May 26, the international medical journal "Journal of the American Medical Association" (JAMA) published the interim analysis results of the Phase 3 clinical trial of the COVID-19 inactivated virus vaccine published by Sinopharm Sino Biotech.

The data shows that the two inactivated vaccines WIV04 (5 µg/dose) and HB02 (4 µg/dose) developed by Wuhan Institute of Biological Products (WIBP) and Beijing Institute of Biological Products (BIBP) are effective in preventing COVID-19.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Top Product

$1.6-1.65/G FOB

P-tolylacetic acid

CAS No.: 622-47-9

Industrial Grade or Medical grade

$1/MT EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.